NCT06444256

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder: A Pilot Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.

Conditions

• Stimulant Use Disorder

Interventions

Type	Name	Description
DRUG	SUVO	Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
DRUG	TAU	Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.

Timeline

• Start date: 2024-07-25
• Primary completion: 2027-01-30
• Completion: 2027-01-30
• First posted: 2024-06-05
• Last updated: 2025-09-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study